- About Us
- News & Events
- TCRN Flagships
- HSA Biobank
- TCRN Grants
- Members
- Consumers
- Education
- Contact Us
Prince of Wales Hospital Grand Rounds: October 2014 - Ga-68; Transitioning Nuclear Medicine from SPECT to PET Professor Rod Hicks is the Director of Cancer Imaging at the Peter MacCallum Cancer Centre, Melbourne. He is head of the Molecular Imaging and Targeted Therapeutics Laboratory. Professor Hicks installed one of the first PET/CT systems in the world in 2001. Since then, he has been actively involved in the development and validation of novel imaging probes and has also pioneered the development of radionuclide therapy in Australia, especially the use of Sr-89, I-131 MIBG, I-131 rituxan, In-111 octreotide and Lu-177 octreotate, with a particular interest in treatment of neuroendocrine tumours and neuroblastoma.
| ||
Prince of Wales Hospital Grand Rounds: July 2014 - Health and Biomedical Big Data for Translational Research Professor Li has been a pioneer of Medical Informatics research in Taiwan. Professor Li Professor Li gave a presentation on the availability of tools and data sets that can facilitate the speed of translational research through big data application. Professor Li introduced attendees to established and emerging biomedical informatics resources, and taking advantage of vast resources of genomics/clinical data currently available in the public domain. |
| |
Prince of Wales Hospital Grand Rounds: January 2014 - The Nelune Comprehensive Cancer Centre and the Australian Advanced Treatment Centre Watch presentation by Professor Robyn Ward as she introduces the project which will deliver the Nelune Comprehensive Cancer Centre and Australian Advanced Treatment Centre. The Nelune Comprehensive Cancer Centre ("NCCC") will deliver modern facilities and provide an integrated, coordinated, patient-centred approach to the treatment and post-care of patients with cancer and blood disorders across the Randwick Hospitals Campus, which includes the Prince of Wales Hospital, the Royal Hospital for Women and the Sydney Children’s Hospital. The Australian Advanced Treatment Centre ("AATC") will provide a purpose-built environment for clinical trial activities. The AATC is a joint venture of UNSW Australia and Nucleus Network Limited and is the first publicly funded, purpose built early phase clinical trials centre in New South Wales. In addition to first into human and first into patient studies, the facility will also support later phase trials across a broad range of disciplines. | ||
2013 NSW Health Innovation Symposium: Connecting Minds - 11 October 2013- Translating Research Into CarePresented by Professor Robyn WardThe 2013 NSW Health Innovation Symposium featured 63 presentations on ground-breaking health initiatives that harness new ideas, new technologies and new approaches to the delivery of patient care. By embracing innovation through collaboration between our health care professionals and consumers, carers, the workforce, the broader community and non-government providers, real advances are being made. The result is both an improvement in how we work and better outcomes for patients. |
| |
TCRN Cancer Challenge of the Year ("CCY") - 2012 Cancer Challenge: "Spaced Education: a tool to translate pain assessment and management evidence into practice."Principal Investigator: Jane Phillips, Sacred Heart Hospice
The 2012 TCRN CCY; Spaced Education: a tool to translate pain assessment and management evidence into practice – addresses the important clinical issue of sub-optimal pain management. By instituting the routine use of a validated online case-based learning application, the project intends to improve cancer pain assessment and reassessment practices across the TCRN, with the ultimate aim of improving cancer patients’ reported pain outcomes. The focus of the CCY is on creating solutions to today’s priority problems in order to make rapid and appropriate gains in the improvement of cancer patient care and treatment outcomes. Therefore, CCY targets research initiatives capable of producing a demonstrable outcome within a 12-15 month period. | ||
| ||
|